Integra LifeSciences Holdings Corporation
IART
$13.09
$0.030.23%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.57% | -0.61% | 3.74% | 11.49% | -0.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.57% | -0.61% | 3.74% | 11.49% | -0.41% |
| Cost of Revenue | 5.79% | 11.36% | 12.41% | 12.04% | 6.50% |
| Gross Profit | 5.41% | -8.61% | -2.14% | 11.12% | -5.02% |
| SG&A Expenses | 1.21% | -2.65% | 2.81% | 22.48% | 11.33% |
| Depreciation & Amortization | -0.85% | 1.27% | 21.72% | 22.45% | 17.21% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.82% | 3.22% | 6.94% | 17.92% | 9.33% |
| Operating Income | 58.76% | -30.74% | -22.28% | -15.61% | -55.97% |
| Income Before Tax | 66.49% | -3,396.56% | -474.30% | -21.89% | -209.42% |
| Income Tax Expenses | 85.31% | -1,584.48% | -143.36% | -65.58% | -988.63% |
| Earnings from Continuing Operations | 49.47% | -3,803.18% | -670.89% | -2.01% | -154.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 49.47% | -3,803.18% | -670.89% | -2.01% | -154.85% |
| EBIT | 58.76% | -30.74% | -22.28% | -15.61% | -55.97% |
| EBITDA | 28.36% | -8.44% | -3.38% | 1.69% | -30.28% |
| EPS Basic | 49.68% | -3,839.89% | -683.89% | -0.04% | -157.17% |
| Normalized Basic EPS | 61.07% | -55.90% | -42.28% | -25.37% | -71.13% |
| EPS Diluted | 49.71% | -3,839.89% | -683.89% | 0.40% | -158.33% |
| Normalized Diluted EPS | 61.07% | -55.90% | -42.28% | -25.37% | -71.08% |
| Average Basic Shares Outstanding | 0.40% | -0.92% | -1.64% | -1.98% | -4.07% |
| Average Diluted Shares Outstanding | 0.40% | -0.92% | -1.64% | -1.98% | -4.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |